Tech Company Financing Transactions
LigoCyte Pharmaceuticals Funding Round
LigoCyte Pharmaceuticals, based in Bozeman, raised $14.5 million from F-Prime Capital and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
9/30/2009
Transaction Type
Venture Equity
Amount
$14,530,000
Round
Undisclosed
Investors
F-Prime Capital (Benjamin Auspitz)
Novartis Venture Fund (Markus Goebel)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2155 Analysis Drive
Bozeman, MT 59718
USA
Bozeman, MT 59718
USA
Phone
Website
Email Address
Overview
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Donald Beeman
Chief Medical Officer
Paul Mendelman
Chief Scientific Officer
Robert Bargatze
Controller
Larry Mikkola
President
Robert Goodwin
VP - R & D
Charles Richardson
Browse more venture capital transactions:
Prev: 9/30/2009: SeaMicro venture capital transaction
Next: 9/30/2009: Akros Silicon venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs